Efficacy of Rituximab Versus Cyclophosphamide and Mycophenolate for the Treatment of Interstitial Lung Disease in Systemic Sclerosis: A Systematic Review.

Autor:	Parikh A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Francis AJ; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Sreenivasan C; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Pandey M; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., AlQassab O; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Kanthajan T; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., AlEdani EM; Dermatology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Aug 31; Vol. 16 (8), pp. e68279. Date of Electronic Publication: 2024 Aug 31 (Print Publication: 2024).
DOI:	10.7759/cureus.68279
Abstrakt:	Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc), contributing to significant morbidity and mortality in affected individuals. The optimal treatment approach for SSc-associated ILD remains uncertain, with rituximab, cyclophosphamide, and mycophenolate among potential therapeutic options. This systematic review aims to evaluate and synthesize the existing evidence on the efficacy of rituximab compared to cyclophosphamide and mycophenolate for the treatment of ILD in patients with systemic sclerosis. A comprehensive search of the following electronic databases, PubMed, Science Direct, Google Scholar, and Cochrane Library, has been conducted to identify relevant studies, including randomized controlled trials, systematic review and meta-analysis, prospective cohort studies, and retrospective cohort studies. Data on study characteristics, participant demographics, interventions, outcomes, and key findings have been extracted and synthesized. The risk of bias in the included studies has been assessed using appropriate tools such as the Cochrane Bias assessment tool for randomized controlled trials, the New Castle Ottawa tool for cohort studies, and the AMSTAR checklist for systematic reviews and meta-analysis. The research team ultimately selected 15 high-quality studies for review. Rituximab demonstrated similar efficacy to cyclophosphamide and mycophenolate in improving lung function (forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO)), with fewer severe adverse events. Cyclophosphamide, while effective, had higher toxicity, leading to more frequent adverse events such as leukopenia and infections. Mycophenolate showed comparable efficacy to cyclophosphamide but with fewer side effects, making it a well-tolerated alternative. The findings of this systematic review will provide valuable insights into the comparative efficacy of rituximab, cyclophosphamide, and mycophenolate in the management of ILD in systemic sclerosis, informing clinical decision-making and guiding future research in this area. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Parikh et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu